News Center

Home page

Peak Report

News reports

We go to the audit

Release time:

2020-07-22

We went to audit

# May 17 -19 . As a member of the supplier audit team, I visited Changzhou Ruiming, Wuxi Yangjian Huaqiang, Suzhou Haishun, Zhejiang Duoling Pharmaceutical Packaging and other companies with my colleagues and conducted a series of audit work.

As one of the key elements of production, the quality and stability of raw materials and auxiliary materials directly determine the stability of the final product quality. In order to ensure the stability of product quality, our manufacturers conduct supplier audits of raw and auxiliary package suppliers every year. This is an on-site audit, including verifying the authenticity of the supplier's qualification documents and inspection reports, whether they have inspection conditions, etc., as well as reviewing its personnel structure, plant facilities and equipment, material management, production process and production management, and quality control laboratory equipment, instruments, document management, etc.

This is my first time to participate in the audit, although I made a corresponding inspection plan for the basic situation of all the suppliers to be inspected before departure. However, once you arrive at the scene, you will still be nervous and do not know where to start. With the warm reception of the representatives of the supply side, our audit work was carried out in an orderly manner.

First of all, we went to the manufacturers of raw materials and chemical raw materials. Before entering the production area, the reception staff of the other party gave us full oral safety education and issued safety helmets, demonstrating the safety awareness that a chemical plant should have. Their production area and office area have obvious regional isolation, effectively avoid cross-contamination. However, some parts of the production site are not doing very well. For example, the unloading position of the raw materials delivered from the warehouse is too random, which is just the place where solar energy is exposed. The label of the raw materials during feeding was removed in advance. In contrast, our factory has done a better job of on-site management. When the raw materials come, there will also be a special unloading position. The labels of the materials will be on the materials until the end of feeding, so as to avoid confusion. We raised these issues with the manufacturer, and the other party accepted them modestly, dealt with them in a timely manner, and said that they would provide rectification reports after all rectifications.

may be an old customer. The manufacturers of composite film (bag) and aluminum foil for drug packaging are a little too casual in reception. We arrived at the factory on the same day but could not find the reception staff. On the spot, there is a sharp contrast between the packaging material manufacturers and our pharmaceutical companies. Although they are also in the D area, their spot is slightly messy and their concept of clearing the spot is somewhat vague. Due to continuous production, the equipment site is easy to leave materials, and the lack of fixed position is slightly messy. They also made rectification immediately after the site was put forward. For our pharmaceutical factory, it is also necessary to change what we have and encourage what we have not.

The third enterprise we went to is a large listed company. Not only can the production and inspection equipment meet the production and inspection requirements, but also the production line is fully automatic production of industry 4.0 , which is fully automated from equipment operation, material and product transportation. In the workshop, the quality of products is also monitored in real time through the central control room, and the positioning of various items is also standardized. The warehouse is a 4 -storey three-dimensional library, which realizes unmanned operation. Their laboratory even has a separate aluminum plastic machine to do challenging experiments, reflecting their pursuit of product quality excellence. All these are worth learning. The wave of industrial automation upgrading is constantly advancing. Although we have not yet entered that stage, we must always maintain our own improvement to meet this wave.

The last company is an enterprise that produces PVC medicinal hard tablets and various composite hard tablets and composite high-barrier packaging materials. Our host is their QC supervisor. To my surprise, their supervisor QC was born in a health school and took part in the inspection work, but he was quite familiar with their process flow and process parameters. This also makes us realize that no matter what position we are in, we should actively learn what we can come into contact with, especially for the process flow and process parameters in production, showing a kind of professionalism for our own industry. During the audit, we found that their workshop also has a special access to visit, each door has access control, for access control is very good. This is where we can learn from. For a workshop, access control is very important, which can effectively avoid problems such as personnel stringing and pollution.

As a production enterprise, our pharmaceutical factory also accepts the audit of our customers every year. Through this rare audit opportunity, I can look at the supplier from the customer's point of view, from which I can objectively see many problems in daily work and production. The first point is that for the reception of customers, special personnel and sufficient relevant information can make customers have a good impression on us; on the production site, various small details determine the quality of the product and whether the production process meets the customer's standards; records and various inspection reports show the true quality of the product. Taking the essence and removing the dross, we will apply the experience gained during this audit to our daily production work, which will certainly give a great impetus to our future work. (Zheng Nan)

More information

Yunnan peak through the safety standard secondary acceptance

On March 21, Yunnan Jianfeng Cement Company successfully passed the evaluation and acceptance of secondary enterprises for safety production standardization. On the same day, a review team composed of leaders of the Yunnan Provincial Work Safety Supervision Bureau and relevant experts reviewed the implementation of the establishment of Yunnan Jianfeng safety production standardization secondary enterprises. According to the 13 elements involved in the "Standard for Assessment and Rating of Safety Production Standardization in Cement Enterprises", the review team conducted strict assessment and scoring item by item through grouping to check the site and review the data, and finally determined that Yunnan Peak passed the standard acceptance of safety standardization secondary enterprises. Yunnan Jianfeng has always attached great importance to safety production. After passing the three-level safety standard enterprise review in 2015, in order to raise the level of enterprise safety management to a new level, in 2016, it began to create secondary safety standardization. Over the past year, Yunnan Jianfeng has insisted on taking the creation of secondary safety standards as the top priority of production and operation management, and has formulated an implementation plan for production safety standardization in accordance with the requirements of national standardization norms. the content covers production safety responsibility system, education and training, safety inspection, safety facilities management and other safety production management standards, systems and post safety operation procedures, while further strengthening daily safety inspection and regularly organizing emergency plan drills, strengthen the investigation and rectification of potential safety hazards and the supervision of important hazard sources, and further consolidate the foundation of enterprise safety production management. After the review, Zhou Jiping, general manager of Yunnan Jianfeng, said that Yunnan Jianfeng will take this standard as a new starting point. On the basis of consolidating the accident-free achievements in production safety for two consecutive years, it will conscientiously implement the main responsibility of production safety and cultivate

2020

07-30

Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory

News from our newspaper On February 28, the 10th meeting of the 9th Board of Directors of the Group Company reviewed and approved the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman of the Board of Directors." On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biological formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through the cooperation with Yale University, we have obtained the patent authorization and commercial development license of the new anti-cancer chemical drug trasatabine (trokacitabine)(which has obtained the national new drug clinical approval in August 2016), the anti-hepatitis B chemical drug Crevudine (Clevudine). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biology, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly built by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has production workshops for multiple dosage forms such as percolation, tincture, solid preparations and liquid preparations.

2020

07-31

Peak health marketing and a new "play"

Building a New System, Flattening Management, Spike Health Marketing, New "Fit" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original division model, combines all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)

2020

07-31

Peak health marketing and a new "play"

Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)

2020

07-31

Accident-free factory creation enters "second season"

At the beginning of the new year, a major "highlight" of the company's safety and environmental protection management in recent years-the "second quarter" of the establishment of a safety and environmental protection accident-free factory has also begun. Safety and environmental protection accident-free factory creation activities are an important measure for the company to improve the level of on-site management. The first phase of the activity will start on January 1, 2014 and end at the end of 2016 for a period of three years. Since the launch of the activity, all subordinate enterprises of the company have actively organized publicity and training related to safety and environmental protection, strengthened the awareness of safety and environmental protection of all employees, improved the management and operation level of safety and environmental protection; increased investment in safety and environmental protection facilities and equipment; strengthened safety and environmental protection inspection and self-examination and correction of hidden dangers, and timely organized rectification of hidden dangers; strictly assessed the units and relevant responsible persons of the accident, And the accident situation in the group, in order to arouse vigilance and avoid similar accidents. In the past three years, the company's subsidiaries have achieved remarkable results in standardization, safety, and clean operation. Safety and environmental protection accidents have dropped significantly, and no major accidents have occurred, which has effectively promoted the company's safe and civilized production construction. In the 2016 safety and environmental protection accident-free factory establishment assessment conducted a few days ago, a total of 6 units met the accident-free factory standard, of which Yunnan Jianfeng, Jianfeng International Trade and Pharmaceutical Department met the standard for the second consecutive year, and Daye Jianfeng, Qiubin Factory and Cable Company met the standard in the first year. In order to sum up experience and further improve the level of safety and environmental protection management, the Group decided to continue to open

2020

07-31

What will the Chinese Medicine Act bring us?

At the 25th meeting of the Standing Committee of the 12th National People's Congress in December 2016, the the People's Republic of China Chinese Medicine Law (hereinafter referred to as the Chinese Medicine Law) was deliberated and passed, which will come into effect on July 1 this year. As the first comprehensive law that comprehensively and systematically embodies the characteristics of traditional Chinese medicine, the Law of traditional Chinese Medicine clearly stipulates the service of traditional Chinese medicine, the protection and development of traditional Chinese medicine, the training of talents of traditional Chinese medicine, and the scientific research of traditional Chinese medicine. With the change of people's health concept and the continuous innovation of medical mode in recent years, the role of traditional Chinese medicine in health is becoming more and more important. The promulgation of the "Traditional Chinese Medicine Law" has made the development of Chinese medicine more law-based, and it is bound to bring changes to domestic pharmaceutical companies. So, the peak of the pharmaceutical, health products companies will look at the "Chinese Medicine Law", and will have how to deal with it? A few days ago, the reporter interviewed the pharmaceutical companies and peak health technology companies related to the person in charge. What will the Chinese Medicine Act bring us? Reporter: As the general manager of Peak Pharmaceutical, what do you think of the Chinese Medicine Law? Huang Jinlong (Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company): the Law of traditional Chinese Medicine defines the important position and development policy of traditional Chinese medicine. The state encourages traditional Chinese medicine and western medicine to learn from each other, complement each other, coordinate development, give full play to their respective advantages, and promote the integration of traditional Chinese and western medicine. Traditional Chinese medicine is a huge knowledge system, reflecting the Chinese nation's understanding of life, health and disease. It is precisely because of the distinctive characteristics of Chinese medicine that the Law of Chinese Medicine is used in Chinese medicine clinics, Chinese medicine physicians and doctors.

2020

07-31

< 1...49 50 51...61 > 跳转到页